Founded in 2023 and based in Alachua, Florida, Beacon Therapeutics focuses on developing late-stage treatments for X-linked retinitis pigmentosa (XLRP) and preclinical programs for prevalent and rare blinding diseases. Their scientific foundation combines gene therapy with the goal of addressing a range of retinal diseases that can lead to blindness.